A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab
Name:
A plain language summary of the ...
Size:
2.305Mb
Format:
PDF
Description:
Found with Open Access Button
Affiliation
Division of Cancer Sciences, Faculty of Biology, Medicine & Health, The University of Manchester & The Christie NHS Foundation Trust,Manchester Academic Health Science Centre, Manchester, United Kingdom.Issue Date
2023
Metadata
Show full item recordCitation
Spira A, Girard N, Krebs M, Park K, Shu C, Dougherty L, et al. A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab. Future oncology (London, England). 2023 Oct;19(33):2213-25. PubMed PMID: 39189517. Epub 2024/08/27. eng.Journal
Future OncologyDOI
10.2217/fon-2023-0284PubMed ID
39189517Additional Links
https://dx.doi.org/10.2217/fon-2023-0284Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.2217/fon-2023-0284
Scopus Count
Collections
Related articles
- A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab.
- Authors: Spira A, Girard N, Krebs M, Park K, Shu C, Dougherty L, Cho BC
- Issue date: 2023 Oct
- Erratum: Eyestalk Ablation to Increase Ovarian Maturation in Mud Crabs.
- Issue date: 2023 May 26
- A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer.
- Authors: Wu YL, Tsuboi M, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS
- Issue date: 2021 Dec 1
- Afatinib for the treatment of non-small-cell lung cancer with unusual EGFR mutations: a plain language summary.
- Authors: Yang JC
- Issue date: 2023 Feb
- Plain language summary of the development of tepotinib: a treatment for a subtype of non-small cell lung cancer called MET exon 14 skipping.
- Authors: Hallick J, Baird AM, Falchook G, Le X, Hong D, Viteri S, Raskin J, Reinmuth N, Vlassak S, Militaru M, Paik PK
- Issue date: 2023 Mar